top of page

SGLT2i vs DPP4iの有害事象大規模

Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes Obes Metab. 2024 Jan 17. doi: 10.1111/dom.15429. Epub ahead of print. PMID: 38234181.


Diabetes Obes Metab


SGLT2i vs DPP4iで有害事象は、

DKA 2.19(1.74-2.76)
ALI(肝) 0.70(0.56-0.88)
AKI 0.54(0.41-0.73)
性器感染症 4.04(3.46-4.71)
尿路結石 0.51(0.37-0.72)

bottom of page